Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



King's College London - Health: More than a medical matter





Gene therapy to treat HIV shows promise

26 September 2011

By Dr Louisa Petchey

Appeared in BioNews 626

The success of a new gene therapy trait represents a significant step towards a 'functional cure' for HIV, human immunodeficiency virus, US researchers announced this week. By mimicking the effects of a naturally occurring gene mutation that makes an individual resistant to infection, this therapy aims to reduce or eliminate the dependency of HIV patients on antiretroviral drugs.

Out of the six HIV patients treated with the new therapy, which works by stopping the virus from getting inside the white blood cells it normally infects, one patient had completely cleared the virus and a further two saw a ten-fold drop in virus levels, despite not taking any antiretroviral drugs.

'We're over the moon to have seen that in this small phase one study', said Jeff Nichol, the executive president of research at Sangamo BioSciences, the company that funded the trial.

The treatment involves isolating white blood cells called T-cells from patients and then genetically modifying them with a specially designed enzyme which inactivates the CCR5 gene. This gene codes for a receptor that is required for HIV to get inside and infect the T-cells, effectively making them HIV-resistant. These cells can then be transfused back into the body.

We inherit two copies of the CCR5 gene, one from each parent. The patient that responded best in the trial, becoming 'virus-free', already carried one mutated copy of the gene, making it easier to produce T-cells where both copies were defective. Researchers believe this is the key to its success – the treatment worked best in those patients who had the largest number of doubly defective T-cells.

Earlier this year, Timothy Brown from Berlin became the first, and so far the only, person to be cured of HIV after he received multiple blood transfusions from an individual who carried a defective copy of the CCR5 gene. According to WebMD, five percent of the general population carry two mutated copies of the CCR5 gene, while ten percent carry one mutated copy.

Dr Pablo Tebas, the infectious disease clinician who headed up one of the clinical trials, believes the trial 'shows a path forward'. Referring to the Timothy Brown case he said: 'The Berlin patient is only one patient, and it changed research priorities'.

It is likely that the results of this trial will lead to increased research into disrupting the CCR5 gene to treat HIV, but Dr Tebas cautions: 'This is a very small experiment, and I don't think it's a cure by any means'.

The results of the trial were reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, Illinois, but are yet to be published or undergo peer review.

 

SOURCES & REFERENCES
New Scientist | 22 September 2011
 
WebMD | 19 September 2011
 
Science Now | 19 September 2011
 
Reuters | 19 September 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

28 January 2013 - by Matthew Thomas 
Altering the genetic makeup of immune cells could provide them with resistance to HIV... [Read More]
11 June 2012 - by Catherine Murphy 
As the UK's largest HIV charity, Terrence Higgins Trust warmly welcomes the decision by the National Institute for Health and Clinical Excellence (NICE) last month to consult on an updated version of its fertility guideline. The new approach outlined by NICE holds the potential to transform fertility services for men and women living with or affected by HIV in the UK who want to become parents... [Read More]
08 May 2012 - by Helen Brooks 
HIV patients treated over a decade ago with genetically modified immune cells have suffered no serious side effects from the treatment. Although the cells may not have been successful in targeting and killing HIV-infected cells, the results are promising as they bolster the safety credentials of gene therapy for clinical use... [Read More]
05 December 2011 - by Tamara Hirsch 
US scientists have induced long-lasting HIV protection in mice from a single injection. Their study, published in the journal Nature, uses gene therapy to stimulate production of antibodies against the virus... [Read More]

07 March 2011 - by Dr Lux Fatimathas 
American researchers have successfully created immune cells resistant to HIV. T cells, which are the main target of HIV, were isolated from six HIV positive patients and genetically manipulated to confer resistance. The cells were injected back into the same patients and were able to survive and multiply... [Read More]
28 June 2010 - by Ben Jones 
The Wellcome Trust has joined forces with the US National Institute of Health (NIH) to coordinate a major new genetics study in Africa.... [Read More]
21 June 2010 - by Dr Lux Fatimathas 
A human RNA-based gene therapy trial to combat HIV has passed the first safety test. US researchers modified human blood stem cells to make them resistant to the virus.... [Read More]
16 February 2009 - by Alison Cranage 
A case report published in the New England Journal of Medicine last week details a man who was HIV+ and, following a bone marrow transplant, now has no detectable signs of the virus. Human Immunodeficiency Virus (HIV) enters and destroys cells of the immune system, eventually causing... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to Login or Register to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
RISK ASSESSMENT:
BREAST CANCER, PREDICTION AND SCREENING
FREE public event in central London, 6.30pm on Thursday 8 May 2014 - find out more HERE

DataLabel Supplying Printed Labels To The UK For Over 15 Years

ANNIVERSARY APPEAL
Please donate HERE, so that the Progress Educational Trust can continue throughout 2014 (and beyond) while keeping BioNews FREE for you to read

The Progress Educational Trust was shortlisted for the Charity Times Awards 2011

Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE, and give the Progress Educational Trust a regular donation